.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,698,179

« Back to Dashboard

Details for Patent: 5,698,179

Title: Iodinated neuroprobe for mapping monoamine reuptake sites
Abstract:An iodinated neuroprobe is provided for mapping monoamine reuptake sites. The iodinated neuroprobe is of the formula: ##STR1## wherein: R=aryl, substituted aryl, heterocyclic, CO(CH.sub.2).sub.n Y, (CH.sub.2).sub.n CHF.sub.2, and (CF.sub.2).sub.n Y, wherein: Y=Cl, Br, I, (CH.sub.2).sub.m, aryl, substituted aryl, heterocyclic CO.sub.2 H, CO.sub.2 R.sup.3, CO.sub.2 NR.sup.3 R.sup.4, OH, OR.sup.3, CH(OR.sup.3).sub.2, CR.sup.3 (OR.sup.4).sub.2, OC0R.sup.3, OSO.sub.2 R.sup.3, OCONR.sup.3 R.sup.4, OCOOR.sup.3, CONR.sup.3 R.sup.4, NR.sup.3 R.sup.4, NR.sup.3 COR.sup.4, NR.sup.3 CO.sub.2 R.sup.4, NR.sup.3 CONR.sup.4 R.sup.5, NCS, NCO; R.sup.3, R.sup.4 and R.sup.5 =alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, or heterocyclic; m=3-8; and n=1-6; R'=C.sub.w H.sub.2w+1 wherein w=0-6 and C includes an isotope of carbon; and X=an isotope of Cl, an isotope of Br, an isotope of F, an isotope of I, or Sn(R".sub.1 R".sub.2 R".sub.3), wherein R".sub.1 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group; R".sub.2 =a CH.sub.p+1 group where p=1-6, or an aryl group; and R".sub.3 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group. Related analogs are also provided. Additionally, a precursor of a radiolabeled neuroprobe and a kit for preparing the iodinated neuroprobe are provided.
Inventor(s): Neumeyer; John L. (Wayland, MA), Milius; Richard A. (Boston, MA), Innis; Robert B. (Hamden, CT)
Assignee: Neuro Imaging Technologies, LLC (Boston, MA)
Filing Date:Jun 06, 1995
Application Number:08/468,575
Claims:1. A neuroprobe for mapping monoamine reuptake sites, the neuroprobe having the formula: ##STR3## wherein R=(CH.sub.2).sub.n OSO.sub.2 R.sup.3 ;

wherein R.sup.3 =alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, and heterocyclic; and n=1-6;

R'=C.sub.w H.sub.2w+1 wherein w=0-6 and C includes an isotope of carbon; and

X=an isotope of Cl, an isotope of Br, an isotope of F, an isotope of I, or Sn(R".sub.1 R".sub.2 R".sub.3), wherein

R".sub.1 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group;

R".sub.2 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group; and

R".sub.3 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group.

2. The neuroprobe of claim 1, wherein the iodine atom is a radioactive isotope of iodine.

3. The neuroprobe of claim 2, wherein the radioactive isotope of iodine is selected from the group consisting of .sup.123 I, .sup.125 I, and .sup.131 I.

4. The neuroprobe of claim 1, wherein in R', C includes a radioactive isotope of carbon.

5. A kit for preparing a radiolabeled neuroprobe for mapping monoamine reuptake sites, the kit comprising:

a precursor of the formula: ##STR4## wherein R=(CH.sub.2).sub.n OSO.sub.2 R.sup.3 ;

wherein R.sup.3 =alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, and heterocyclic; and n=1-6;

R'=C.sub.w H.sub.2w+1 wherein w=0-6 and C includes an isotope of carbon; and

X=an isotope of Cl, an isotope of Br, an isotope of F, an isotope of I, or Sn (R".sub.1 R".sub.2 R".sub.3) wherein

R".sub.1 =a C.sub.p H.sub.2p+1 group where p=1-6 or an aryl group;

R".sub.2 =a C.sub.p H.sub.2p+1 group where p=1-6 or an aryl group; and

R".sub.3 =a C.sub.p H.sub.2p+1 group where p=1-6, or an aryl group.

6. The kit of claim 5, wherein said isotope of I is a radioactive isotope of iodine.

7. The kit of claim 6, wherein said isotope of I is selected from the group consisting of .sup.123 I, .sup.125 I, and .sup.131 I.

8. The kit of claim 6, wherein the precursor is reacted in the presence .sup.18 F.

9. The kit of claim 8, wherein the .sup.18 F is selected from the group consisting of Na.sup.18 F, K.sup.18 F, and Cs.sup.18 F.

10. The kit of claim 8, wherein said .sup.18 F is complexed with a reagent of the formula M.sup.+ X.sup.-, wherein:

M.sup.+ =a complex of 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane and one of K, Na, Ce, Ru, a tetraalkylammonium ion, and an ion exchange resin functionalized with quaternary amine groups; and

X.sup.- =carbonate, bicarbonate, hydroxide, and formate.

11. The kit of claim 5, wherein in R', C includes a radioactive isotope of carbon.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc